Literature DB >> 28515255

Active Systemic Treatment of Pancreatic Cancer.

Margaret Tempero1.   

Abstract

By 2020, pancreatic cancer is expected to be the second most common cause of cancer-related death, exceeded only by lung cancer. During her presentation at the NCCN 22nd Annual Conference, Dr. Margaret Tempero offered an update on the current state of systemic treatment of pancreatic cancer, focusing on resectable/borderline resectable, locally advanced, and metastatic disease.
Copyright © 2017 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Year:  2017        PMID： 28515255     DOI： 10.6004/jnccn.2017.0084

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  2 in total

1.  Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis.

Authors:  Márton Benke; Nelli Farkas; Péter Hegyi; Benedek Tinusz; Patrícia Sarlós; Bálint Erőss; Kata Szemes; Nóra Vörhendi; Zsolt Szakács; Ákos Szücs
Journal:  Pathol Oncol Res       Date:  2022-05-10       Impact factor: 2.874

2.  Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.

Authors:  Dan Wang; Chongshun Liu; Yuan Zhou; Tingyu Yan; Chenglong Li; Qionghui Yang; Yang Xu; Lilan Zhao; Qian Pei; Fengbo Tan; Cenap Güngör; Yuqiang Li
Journal:  Radiat Oncol       Date:  2020-05-13       Impact factor: 3.481
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.